Lupkynis is approved by the UK MHRA to treat active lupus nephritis
Lupkynis (voclosporin) has been approved in Great Britain as a treatment for adults with active lupus nephritis by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA), Aurinia Pharmaceuticals, the therapy’s developer, announced
The MHRA’s approval came just a few months after the European Commission approved Lupkynis for the same indication in all EU member states. The therapy was approved in the U.S. in 2021. According to Aurinia, Lupkynis is the first oral medicine approved in the U.S. and Europe to treat active lupus nephritis, which is a serious complication of systemic lupus erythematosus (SLE), characterized by kidney inflammation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins